Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Critical Care
    • Oral Ciprofloxacin as...

    Oral Ciprofloxacin as good as IV antibiotics in bacteremia

    Written by Vinay Singh singh Published On 2018-10-09T20:10:43+05:30  |  Updated On 9 Oct 2018 8:10 PM IST
    Oral Ciprofloxacin as good as IV antibiotics in bacteremia

    A new study has found oral ciprofloxacin as an effective treatment against gram-negative bacteremia, according to the findings of a study presented at IDWeek 2018 held October 3-7 in San Francisco, California.


    Not much evidence has been gathered to guide effective treatment of gram-negative bacteremia. Gregory Cook and his associates conducted a single centered retrospective cohort study to evaluate outcomes in patients who were treated with highly bioavailable oral antibiotics compared with patients treated with intravenous antibiotics.


    The study was conducted between January 2015 and December 2017 at Froedtert & the Medical College of Wisconsin in patients requiring hospitalization with one or more positive blood cultures for a gram-negative organism.


    The study participants were split into two groups. 98 patients received an intravenous antibiotic and 103 patients received a highly bioavailable oral antibiotic. Treatment failure was defined as a “composite of all-cause mortality and recurrent bacteremia or recurrent primary site infection.” The primary endpoint was 90-day treatment failure and the secondary outcomes consisted of 30-day treatment failure, 30- and 90-day all-cause mortality, and 30- and 90-day recurrent infections.


    Patients in the intravenous treatment group were more often found to be immunosuppressed (41% vs 22%). Pitt Bacteremia scores in both groups were similar and source control achievement was also similar. The most common source of bacteremia was found to be urine, and Escherichia coli was the most common pathogen.


    Read Also: Even a shorter course of antibiotics effective in Gram-negative Bacteremia


    Key study findings:




    • In the intravenous antibiotic group, 90-day treatment failure occurred in 16 patients and occurred in 2 patients from the highly bioavailable oral antibiotic group (16.8% vs 1.9%).

    • Both groups showed similar 30-day mortality (4.5% vs. 0%).

    • At 30-days, treatment failure occurred in 0 patients from the highly bioavailable oral antibiotic group and in 6 patients from the intravenous antibiotic patient group (6.3% vs 0%).

    • Infection reoccurred after 90-days in 10 patients in the intravenous group and 1 in the oral antibiotic group (10.5% vs 1%).

    • Using logistic regression analysis, the researchers adjusted for potential confounders and found that “no characteristics correlated with treatment failure other than [intravenous antibiotic] therapy.

    • A potential issue with this study may be its small scope; it drew from a single location's data and included a total of only 201 patients. While all results presented were statistically significant, these findings may warrant a larger scale investigation.


    Read Also: Levofloxacin With Chemo Reduces Bacteremia in Pediatric Leukemia


    According to the authors, the limitation of the study may be its small scope as the data was drawn from a single location which included a total of only 201 patients.


    "While all results presented were statistically significant, these findings may warrant a larger scale investigation,’ write the authors.

    californiaCiprofloxacinFroedtert & the Medical CollegeGram negativeIDWeekintravenousmortalityoralSan Franciscotherapytreatmentupdates
    Source : press release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Vinay Singh singh
    Vinay Singh singh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok